No Data
Trending Industry Today: AKESO Leads Losses In Biotechnology Stocks
Bull market sentiment? The WuXi group drives the Sector to explode, high position funds are still trapped, and Fund managers predict that the Innovative Drugs market will last throughout the year.
① The WuXi system has driven a significant rise in the pharmaceutical Sector, the Innovative Drugs bull has arrived; ② Feedback from fund investors: the Fund has rebounded, but has not returned to the original investment; ③ Investors are most concerned about whether the market can continue.
WuXi AppTec GAAP EPS of RMB3.22, Revenue of RMB39.24B; Initiates 2025 Outlook
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
WUXI APPTEC held strong! Achieved 2024 performance guidance, expecting to achieve double-digit growth in revenue this year | Interpretations
In 2024, WUXI APPTEC's revenue and net profit saw a slight decline year-on-year, but it still achieved the performance guidance set at the beginning of last year; Despite the ongoing disturbances from the "Biotechnology Safety Act", customers and Orders still experienced substantial growth in 2024; WUXI APPTEC expects to achieve double-digit growth of 10-15% this year.
Express News | Hong Kong Indexes Rally, Blue-Chip Stocks Rise; Some Industry-Leading Stocks Surge. U.S. Listed Chinese Equities Trade Higher in Overnight Trading
COWmustMoo : this one may be a VCP break up
COWmustMoo : nice daily chart.. hourly too
AaronW : How many shares of WuXi AppTec are held, has the value of the sellable financial Assets appreciated?